[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy

A. A. Martoni, S. Fanti, C. Zamagni, M. Rosati, P. De Iaco, A. D'Errico Grigioni, P. Castellucci, S. Quercia, A. Musto, L. Ricci Maccarini, E. Lopci, A. Bernardi

Research output: Contribution to journalArticle

Abstract

Aim. The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses. [18F]FDG-PET/CT monitoring during na-CHT could predict early pathological response and allow the delivery of an optimal na-CHT duration. Methods. Consecutive patients with AOC unsuitable for optimal upfront surgery and fit for na-CHT were monitored by FDG-PET/CT at baseline and after 3 and 6 courses of carboplatin-paclitaxel CHT. At the end of na-CHT patients were re-evaluated to undergo definitive optimal surgery (i.e. without post-surgical residual disease). Percentage changes in maximal standardized uptake value (Δ-SUVmax) were compared with the pathological response. Only patients with pathological complete response (pCR) or minimal residual disease (pMRD) were considered as pathological responders (pR), while all the other cases were considered non-responders (NR). Results. Baseline FDG-PET/CT was abnormal in all 42 enrolled patients (median SUVmax 11, range 3-20). After 3 and 6 courses median SUVmax decreased to 3 (

Original languageEnglish
Pages (from-to)81-90
Number of pages10
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume55
Issue number1
Publication statusPublished - Feb 2011

Keywords

  • Adjuvant chemotherapy
  • Fluorodeoxyglucose F18
  • Ovarian neoplasms
  • Positron emission tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Martoni, A. A., Fanti, S., Zamagni, C., Rosati, M., De Iaco, P., D'Errico Grigioni, A., Castellucci, P., Quercia, S., Musto, A., Ricci Maccarini, L., Lopci, E., & Bernardi, A. (2011). [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 55(1), 81-90.